"Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION).
| Descriptor ID |
D015513
|
| MeSH Number(s) |
D12.776.624.664
|
| Concept/Terms |
Oncogene Proteins- Oncogene Proteins
- Proteins, Oncogene
- Oncogene Products
- Products, Oncogene
- Oncoproteins
- Oncogene Product
- Product, Oncogene
- Oncogene Protein
- Protein, Oncogene
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins".
This graph shows the total number of publications written about "Oncogene Proteins" by people in this website by year, and whether "Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 |
| 1995 | 7 | 0 | 7 |
| 1996 | 6 | 2 | 8 |
| 1997 | 3 | 4 | 7 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 6 | 2 | 8 |
| 2002 | 5 | 3 | 8 |
| 2003 | 1 | 7 | 8 |
| 2004 | 0 | 7 | 7 |
| 2005 | 13 | 6 | 19 |
| 2006 | 9 | 3 | 12 |
| 2007 | 1 | 1 | 2 |
| 2008 | 7 | 7 | 14 |
| 2009 | 8 | 2 | 10 |
| 2010 | 7 | 1 | 8 |
| 2011 | 5 | 4 | 9 |
| 2012 | 4 | 6 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 8 | 6 | 14 |
| 2015 | 6 | 1 | 7 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 4 | 6 |
| 2018 | 4 | 2 | 6 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins" by people in Profiles.
-
SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation. Commun Biol. 2024 01 09; 7(1):67.
-
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
-
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
-
Genome-wide association study of gastric cancer- and duodenal ulcer-derived Helicobacter pylori strains reveals discriminatory genetic variations and novel oncoprotein candidates. Microb Genom. 2021 11; 7(11).
-
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep Med. 2021 09 21; 2(9):100394.
-
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719.
-
Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol. 2021 06; 34(6):1143-1152.
-
Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 02; 7(6).
-
Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020 06; 34(6):1626-1636.
-
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10.